LB Pharmaceuticals expects Phase 3 NOVA-2 LB-102 schizophrenia topline data in H1 2027 - LBRX News | RalliesLB Pharmaceuticals expects Phase 3 NOVA-2 LB-102 schizophrenia topline data in H1 2027
L
LBRX• Phase 3 NOVA-2 readout pulled forward to H1 2027
- LB Pharmaceuticals pulled forward expected topline results from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia to H1 2027.
- Results have not been presented yet.
- The timing shift reflects faster-than-expected enrollment in the pivotal, placebo-controlled study.
- The company now targets a pre-NDA meeting with the FDA in H2 2027, contingent on the NOVA-2 readout.
GTHP
•
